Solithromycin, an oral antibiotic manufactured by Cempra Inc and prescribed against community-acquired bacterial pneumonia (CAPB) has won the approval of health authorities after it performed excellently at its late-stage trial. This success qualifies this drug for approval by the FDA and it might soon hit the market once its approval scales through.
A next generation class of antibiotics known as macrolides, Cempra’s solithromycin has been proven effective at combating CAPB, which has been the leading cause of death from community infections that is characterized by cough and fever, and shortness of breath among others. About 5-10 million peopl...
Also read: Tyson Seeks Lead in No-Antibiotics Poultry